Literature DB >> 20547790

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.

Werner Christian Neubauer1, Monika Engelhardt, Armin König, Stefanie Hieke, Manfred Jung, Hartmut Bertz, Klaus Kümmerer.   

Abstract

Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 microg/liter versus 1,125 microg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20547790      PMCID： PMC2934950          DOI： 10.1128/AAC.00150-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

Authors:  Angela Sansone-Parsons; Gopal Krishna; Angela Calzetta; David Wexler; Bhavna Kantesaria; Mitchell A Rosenberg; Marc A Saltzman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.

Authors:  Paul O Gubbins; Gopal Krishna; Angela Sansone-Parsons; Scott R Penzak; Li Dong; Monika Martinho; Elias J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

Authors:  Farkad Ezzet; David Wexler; Rachel Courtney; Gopal Krishna; Josephine Lim; Mark Laughlin
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

6.  HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.

Authors:  Carsten Müller; Margit Arndt; Christian Queckenberg; Oliver A Cornely; Martin Theisohn
Journal:  Mycoses       Date:  2006       Impact factor: 4.377

Review 7.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.

Authors:  Rachel Courtney; Sudhakar Pai; Mark Laughlin; Josephine Lim; Vijay Batra
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 9.  Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

Authors:  R Herbrecht
Journal:  Int J Clin Pract       Date:  2004-06       Impact factor: 2.503

10.  Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.

Authors:  David Lebeaux; Fanny Lanternier; Caroline Elie; Felipe Suarez; Agnès Buzyn; Jean-Paul Viard; Marie-Elisabeth Bougnoux; Marc Lecuit; Vincent Jullien; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191
View more
  11 in total

1.  Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  J J Vehreschild; C Müller; F Farowski; M J G T Vehreschild; O A Cornely; U Fuhr; K-A Kreuzer; M Hallek; V Kohl
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.

Authors:  Piergiorgio Cojutti; Anna Candoni; Erica Simeone; Loretta Franceschi; Renato Fanin; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

3.  Relevance of timing for determination of posaconazole plasma concentrations.

Authors:  Werner J Heinz; Janina Zirkel; Anna Kuhn; Diana Schirmer; Ulrike Lenker; Daniela Keller; Hartwig Klinker
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Inhibition of antifungal therapy by gastric acid suppressants.

Authors:  Harry W Daniell
Journal:  Intensive Care Med       Date:  2015-02-21       Impact factor: 17.440

Review 5.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

6.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 7.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

8.  Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.

Authors:  Anne-Grete Märtson; Anette Veringa; Edwin R van den Heuvel; Martijn Bakker; Daan J Touw; Tjip S van der Werf; Lambert F R Span; Jan-Willem C Alffenaar
Journal:  Mycoses       Date:  2019-06-18       Impact factor: 4.377

9.  Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.

Authors:  Elisabeth Leclerc; David Combarel; Madalina Uzunov; Véronique Leblond; Christian Funck-Brentano; Noël Zahr
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

10.  Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.

Authors:  Daniela Stelzer; Alexandra Weber; Franziska Ihle; Sandhya Matthes; Felix Ceelen; Gregor Zimmermann; Nikolaus Kneidinger; Rene Schramm; Hauke Winter; Michael Zoller; Michael Vogeser; Juergen Behr; Claus Neurohr
Journal:  Ther Drug Monit       Date:  2017-04       Impact factor: 3.681
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.